Clinical trials: APOL1-mediated Kidney Disease
APOL1-mediated Kidney Disease
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.
- Trial name
- NCT05324410
- Testing
- VX-840
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
APOL1-mediated Kidney Disease
APOL1 Genotyping CTA Clinical Performance Study
Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment.
- Trial name
- NCT06839833
- Testing
- APOL1 Genotyping
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Almac Diagnostic Services LLC